CMP Mycophenolate - BDNG

Clinical Management Plan Mycophenolate Mofetil
Patient Name:
Patient medication sensitivities/allergies:
Patient identification e.g. ID number, date of birth:
Independent Prescriber(s):
Condition(s) to be treated
Psoriasis
Eczema
Blistering skin disorders
Medicines that may be prescribed by SP:
Preparation
Indication
Supplementary Prescriber(s)
CNS Ann Davies & CNS Sharon Hulley
Aim of treatment
To control disease and reduce symptoms
Dose schedule
Specific indications for
referral back to the IP
Oral Mycophenolate
Mofetil
Moderate to severe psoriasis
Moderate to severe eczema
Blistering skin disorders e.g.
Bullous Pemphigus
Initial dose of 250-500mg
twice daily, increasing to
a maximum dose of one
gram twice daily
When psoriasis improves
reduce Mycophenolate to
the lowest dose that will
maintain adequate control
of condition.
As specified in BNF
Low Hb (< 10),
WBC

Clinical Management Plan Mycophenolate Mofetil
Frequency of review and monitoring by:
Supplementary prescriber
As per departmental algorithm
Supplementary prescriber and independent prescriber
12 months or sooner if there are complications
Process for reporting ADRs:
Write to GP
Report to independent prescriber.
Yellow card if severe drug reaction
Shared record to be used by IP and SP:
Patients medical notes
Agreed by independent
prescriber(s)
Date
Agreed by supplementary
prescriber(s)
Date
Date agreed with
patient/carer